Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
43.67
+0.58 (1.35%)
At close: Jun 27, 2025, 4:00 PM
43.51
-0.16 (-0.37%)
After-hours: Jun 27, 2025, 4:45 PM EDT
Exelixis Employees
Exelixis had 1,147 employees as of December 31, 2024. The number of employees decreased by 163 or -12.44% compared to the previous year.
Employees
1,147
Change (1Y)
-163
Growth (1Y)
-12.44%
Revenue / Employee
$2,004,291
Profits / Employee
$561,086
Market Cap
11.91B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,147 | -163 | -12.44% |
Dec 31, 2023 | 1,310 | 87 | 7.11% |
Dec 31, 2022 | 1,223 | 269 | 28.20% |
Dec 31, 2021 | 954 | 181 | 23.42% |
Dec 31, 2020 | 773 | 156 | 25.28% |
Dec 31, 2019 | 617 | 133 | 27.48% |
Dec 31, 2018 | 484 | 112 | 30.11% |
Dec 31, 2017 | 372 | 85 | 29.62% |
Dec 31, 2016 | 287 | 172 | 149.57% |
Dec 31, 2015 | 115 | 17 | 17.35% |
Dec 31, 2014 | 98 | -129 | -56.83% |
Dec 31, 2013 | 227 | 53 | 30.46% |
Dec 31, 2012 | 174 | -26 | -13.00% |
Dec 31, 2011 | 200 | -183 | -47.78% |
Dec 31, 2010 | 383 | -293 | -43.34% |
Dec 31, 2009 | 676 | 0 | - |
Dec 31, 2008 | 676 | -59 | -8.03% |
Dec 31, 2007 | 735 | 84 | 12.90% |
Dec 31, 2006 | 651 | 101 | 18.36% |
Dec 31, 2005 | 550 | 33 | 6.38% |
Dec 31, 2004 | 517 | -56 | -9.77% |
Dec 31, 2003 | 573 | 23 | 4.18% |
Dec 31, 2002 | 550 | -21 | -3.68% |
Dec 31, 2001 | 571 | 214 | 59.94% |
Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
EXEL News
- 5 days ago - Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment - Seeking Alpha
- 5 days ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 5 days ago - Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer - Business Wire
- 8 days ago - Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 5 weeks ago - Product Performance, Big Money Lift Exelixis - FXEmpire
- 5 weeks ago - Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - Business Wire
- 5 weeks ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June - Business Wire
- 6 weeks ago - Exelixis: A Notable Quarter - Seeking Alpha